MULTIMMUNE GMBH
multimmune GmbH, a biopharmaceutical company, engages in the discovery and development of novel products.
MULTIMMUNE GMBH
Industry:
Biotechnology Pharmaceutical
Founded:
1999-01-01
Address:
Regensburg, Bayern, Germany
Country:
Germany
Website Url:
http://www.multimmune.de
Status:
Active
Contact:
+499419445575
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Font Awesome Apache IPv6 PHP PHP 7 Apache 2.4 DigiCert SSL
Similar Organizations
Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.
Arpida AG
Arpida AG is a biopharmaceutical company that focused on the discovery and development of novel products.
Palau Pharma S.A.
PALAU PHARMA is a newly created biopharmaceutical company, whose mission is the discovery and development of drug candidates.
Pomona Ricera
This company is a private discovery-stage biotech company engaged in the design, development and production.
Proacta Therapeutics
Proacta Therapeutics is a biopharmaceutical company, engages in the discovery and development of oncology drugs.
Sea4Us
Sea4Us is a biopharmaceutical company focused on the discovery and development of new pharmaceutical drugs.
Syntarga
Syntarga is a privately held biopharmaceutical company engaged in the discovery and development of proprietary Antibody-Drug Conjugate
Official Site Inspections
http://www.multimmune.de
- Host name: w0e.rzone.de
- IP address: 81.169.145.78
- Location: Berlin Germany
- Latitude: 52.5174
- Longitude: 13.3985
- Timezone: Europe/Berlin
- Postal: 12529
More informations about "multimmune GmbH"
multimmune GmbH - HOME
Multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new …See details»
multimmune GmbH - VISION & MISSION
To reduce cancer deaths and improve the lives of cancer patients by developing revolutionary products which specifically target primary tumors and aggressive, metastatic disease. pipeline …See details»
multimmune GmbH - ABOUT US / CONTACT / IMPRESSUM
Prof. Dr. Gabriele Multhoff, PhD. eMail: [email protected]. Impressum. The Publisher of this website is multimmune GmbH, on behalf of the Management Board. …See details»
Multimmune GmbH - Bayern International – Competence for …
Multimmune GmbH is a private biopharmaceutical company focused on the development of innovative therapeutics for cancers that express heat shock protein 70 (Hsp70). The Company …See details»
multimmune GmbH - Crunchbase Company Profile & Funding
Multimmune GmbH, a biopharmaceutical company, engages in the discovery and development of novel products. An ex vivo therapy that activates natural killer (NK) cells using a synthetic …See details»
multimmune GmbH - LinkedIn
Multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor...See details»
multimmune GmbH - Drug pipelines, Patents, Clinical trials
Explore multimmune GmbH with its drug pipeline, therapeutic area, technology platform, 1 news, and 1 literature, Disease Domain:Neoplasms, Technology Platform:Immune cell therapy, …See details»
multimmune GmbH Company Profile | München, Bayern, Germany ...
Multimmune GmbH Company Profile | München, Bayern, Germany | Competitors, Financials & Contacts - Dun & BradstreetSee details»
multimmune Company Profile 2024: Valuation, Funding
Information on valuation, funding, acquisitions, investors, and executives for multimmune. Use the PitchBook Platform to explore the full profile.See details»
multimmune GmbH - NEWS & PUBLICATIONS
News and Updates are now collated on our L inkedin page. multimmune's platform technologies have been fully evaluated in the pre-clinical setting, and data widely published in the …See details»
multimmune GmbH Profile - medical-xprt.com
Multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new …See details»
Multimmune - Products, Competitors, Financials, Employees, …
Multimmune is a clinical-stage biopharmaceutical company focused on developing innovative cancer theranostics. Use the CB Insights Platform to explore Multimmune's full profile.See details»
A. Graham Pockley, PhD – Chief Executive Officer – multimmune …
CEO, multimmune GmbH / Emeritus Professor / Cancer Immunobiology & Immunotherapy / Entrepreneur · I am the CEO of multimmune GmbH, Munich, Emeritus Professor of …See details»
multimmune - Overview, News & Similar companies | ZoomInfo.com
Feb 3, 2021 · Multimmune GmbH is a clinical-stage biopharmaceutical company in Munich, Germany that has developed a proprietary Hsp70 targeted platform to redire ct NK cells to …See details»
multimmune GmbH - PLATFORM TECHNOLOGY
Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful product, termed ENKASTIM which allows, for the first time, a unique and specific activation of …See details»
Alphageneron Pharmaceuticals Signed Exclusive License
Feb 4, 2021 · Multimmune GmbH is a clinical-stage biopharmaceutical company in Munich, Germany that has developed a proprietary Hsp70 targeted platform to redirect NK cells to treat …See details»
Multimmune GmbH - BioCentury Company Profiles - BCIQ
Jan 15, 2015 · Multimmune GmbH - BioCentury Company Profiles for the biopharma industrySee details»
multimmune GmbH - mi-DIAGNOSTICS PIPELINE
Multimmune's goal is to build a well-staged pipeline of differentiated products for identifying patients that will respond to membrane Hsp70-directed therapies, for the diagnosis and …See details»
Multimmune - Company Profile - Tracxn
Oct 21, 2024 · Multimmune - Developer of therapeutics for the treatment of cancer. Raised funding from 4 investors. Multimmune has 708 competitors.See details»
multimmune GmbH - FOR PATIENTS
The safety and tolerability of ex vivo TKD / IL-2 stimulated, autologous NK cells (ENKASTIM-ev) has previously been demonstrated in patients with metastasized colorectal and non-small cell …See details»